TLSA
Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom.
Tiziana Life Sciences Ltd (TLSA) is rated C- (2.0/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Momentum (D+). The rating has held at C- for 6 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-15 | C+ (2.5) | D+ (1.7) | D+ (1.6) | D+ (1.6) | C+ (2.6) | C- (2.0) |
| 2026-11-08 | C+ (2.5) | D+ (1.5) | D+ (1.6) | C- (1.9) | C+ (2.6) | C- (2.0) |
| 2026-11-01 | C+ (2.5) | D+ (1.6) | D+ (1.6) | C (2.3) | C+ (2.7) | C- (2.1) |
| 2026-10-25 | C+ (2.5) | D+ (1.7) | D+ (1.6) | C (2.3) | C+ (2.6) | C- (2.1) |
| 2026-10-18 | C+ (2.5) | D+ (1.6) | D+ (1.6) | C (2.3) | C+ (2.6) | C- (2.1) |